Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up.

Open access

Abstract

Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. Aims: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. Methods: This randomized, waiting-list controlled study enrolled 27 patients aged 21–75 with moderate to severe unipolar depression (GRID-Hamilton Depression Rating Scale (GRID-HAMD) ⩾ 17). Participants were randomized to an immediate or delayed (8 weeks) treatment condition in which they received two doses of psilocybin with supportive psychotherapy. Twenty-four participants completed both psilocybin sessions and were followed through 12 months following their second dose. Results: All 24 participants attended all follow-up visits through the 12-month timepoint. Large decreases from baseline in GRID-HAMD scores were observed at 1-, 3-, 6-, and 12-month follow-up (Cohen d = 2.3, 2.0, 2.6, and 2.4, respectively). Treatment response (⩾50% reduction in GRID-HAMD score from baseline) and remission were 75% and 58%, respectively, at 12 months. There were no serious adverse events judged to be related to psilocybin in the long-term follow-up period, and no participants reported psilocybin use outside of the context of the study. Participant ratings of personal meaning, spiritual experience, and mystical experience after sessions predicted increased well-being at 12 months, but did not predict improvement in depression. Conclusions: These findings demonstrate that the substantial antidepressant effects of psilocybin-assisted therapy may be durable at least through 12 months following acute intervention in some patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/02698811211073759

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Decrease in GRID-HAMD depression scores over time from baseline through the 12-month follow-up (N = 24). Data points are means and brackets are ±1 SD; lower brackets are truncated at GRID-HAMD scores of 0. Mean GRID-HAMD was 22.8 (3.9) at baseline, 8.7 (7.6) at 1 week, 8.9 (7.4) at 4 weeks, 9.3 (8.8) at 3 months, 7.0 (7.7) at 6 months, and 7.7 (7.9) at 12 months post-treatment. All timepoints were significantly different from baseline (p < 0.001). Cohen d effect size is shown for each timepoint. Cohen d (95% CI) was 2.3 (1.5–3.1) at 1 week, 2.3 (1.5–3.1) at 4 weeks, 2.0 (1.3–2.7) at 3 months, 2.6 (1.7–3.4) at 6 months, and 2.4 (1.6–3.2) at 12 months.
Figure 1. Decrease in GRID-HAMD depression scores over time from baseline through the 12-month follow-up (N = 24). Data points are means and brackets are ±1 SD; lower brackets are truncated at GRID-HAMD scores of 0. Mean GRID-HAMD was 22.8 (3.9) at baseline, 8.7 (7.6) at 1 week, 8.9 (7.4) at 4 weeks, 9.3 (8.8) at 3 months, 7.0 (7.7) at 6 months, and 7.7 (7.9) at 12 months post-treatment. All timepoints were significantly different from baseline (p < 0.001). Cohen d effect size is shown for each timepoint. Cohen d (95% CI) was 2.3 (1.5–3.1) at 1 week, 2.3 (1.5–3.1) at 4 weeks, 2.0 (1.3–2.7) at 3 months, 2.6 (1.7–3.4) at 6 months, and 2.4 (1.6–3.2) at 12 months.CC BY-NC · PubMed Central
Figure 2. Depression scores (GRID-HAMD) for each of 24 study participants at baseline and each of 5 follow-up assessment timepoints. Individual participants are represented with different colors. Dashed lines indicate three participants who did not fulfill criteria for a treatment response at any post-treatment timepoint. Enlarged data points indicate participants who reported treatment with antidepressant medication, with the left-most enlarged data points showing the first follow-up timepoint at which medication use was reported.
Figure 2. Depression scores (GRID-HAMD) for each of 24 study participants at baseline and each of 5 follow-up assessment timepoints. Individual participants are represented with different colors. Dashed lines indicate three participants who did not fulfill criteria for a treatment response at any post-treatment timepoint. Enlarged data points indicate participants who reported treatment with antidepressant medication, with the left-most enlarged data points showing the first follow-up timepoint at which medication use was reported.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. Depression Rating Scale Standardization Team, 2003, GRID-HAMD-17, GRID-HAMD-21 structured interview guide

Cited by

See all 425

Metadata

Authors
Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R.
Affiliations
Johns Hopkins University (US)
Corresponding author
  • Gukasyan, Natalie
  • Griffiths, Roland R
Venue
Journal of Psychopharmacology
Published
2022-02
Volume
36
Issue
2
Pages
151-158
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W4212903385
Cited by
425
References
39
Citations by year
2026: 61 · 2025: 88 · 2024: 136 · 2023: 106 · 2022: 33
FWCI
82.76
Type
journal article
Language
en
Open access
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Institute on Drug Abuse (T32DA07209)
  • Crowdfunding campaign organized by Tim Ferriss
  • Philanthropic support from the Steven and Alexandra Cohen Foundation, Tim Ferriss, Matt Mullenweg, Craig Nerenberg, and Blake Mycoskie
  • Dave Morin
  • Riverstyx Foundation
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
psilocybin, psilocybin-assisted therapy, major depressive disorder, antidepressant efficacy, long-term follow-up, remission, supportive therapy, adverse events, mystical experience, spiritual experience, personal meaning, well-being
MeSH terms
Adult, Aged, Antidepressive Agents, Combined Modality Therapy, Major Depressive Disorder, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Prospective Studies, Psilocybin, Psychiatric Status Rating Scales, Psychotherapy, Time Factors, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. https://app.cochat.ai/papers/10.1177/02698811211073759
The paper
Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. Journal of Psychopharmacology. https://doi.org/10.1177/02698811211073759

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.